Literature DB >> 24391131

Leishmania donovani targets tumor necrosis factor receptor-associated factor (TRAF) 3 for impairing TLR4-mediated host response.

Purnima Gupta1, Jayeeta Giri, Supriya Srivastav, Ajit G Chande, Robin Mukhopadhyaya, Pijush K Das, Anindita Ukil.   

Abstract

Intramacrophage pathogen Leishmania donovani escapes host immune response by subverting Toll-like receptor (TLR) signaling, which is critically regulated by protein ubiquitination. In the present study, we identified tumor necrosis factor receptor-associated factor (TRAF) 3, degradative ubiquitination of which is essential for TLR4 activation, as a target for Leishmania to deactivate LPS-mediated TLR4 signaling. We used LPS-treated RAW 264.7 cells and compared the TLR4-mediated immune response in these cells with L. donovani and L. donovani + LPS costimulated macrophages. TRAF3, which was ubiquitinated (2.1-fold over control) at lys 48 position and subsequently degraded following LPS treatment, persisted in L. donovani and L. donovani + LPS costimulated cells due to defective lys 48 ubiquitination. Lys 63-linked ubiquitination of upstream proteins in the cascade (cIAP1/2 and TRAF6), mandatory for TRAF3 degradation, was also reduced postinfection. This may be attributed to reduced association between ubiquitin-conjugating enzyme Ubc13 and TRAF6 during infection. Inhibition of TRAF3 before infection by shRNA in Balb/c mice showed enhanced IL-12 and TNF-α (10.8- and 8.1-fold over infected control) and decreased spleen parasite burden (61.3% suppression, P<0.001), thereby marking reduction in disease progression. Our findings identified TRAF3 as a novel molecular regulator exploited by Leishmania for successful infection.

Entities:  

Keywords:  macrophage; signalosome; ubiquitination

Mesh:

Substances:

Year:  2014        PMID: 24391131     DOI: 10.1096/fj.13-238428

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  15 in total

1.  Leishmania donovani chaperonin 10 regulates parasite internalization and intracellular survival in human macrophages.

Authors:  Lucie Colineau; Joachim Clos; Kyung-Mee Moon; Leonard J Foster; Neil E Reiner
Journal:  Med Microbiol Immunol       Date:  2017-03-11       Impact factor: 3.402

2.  Characterization of microRNA expression profiles in Leishmania-infected human phagocytes.

Authors:  N S Geraci; J C Tan; M A McDowell
Journal:  Parasite Immunol       Date:  2015-01       Impact factor: 2.280

3.  Antileishmanial effect of 18β-glycyrrhetinic acid is mediated by Toll-like receptor-dependent canonical and noncanonical p38 activation.

Authors:  Purnima Gupta; Pijush K Das; Anindita Ukil
Journal:  Antimicrob Agents Chemother       Date:  2015-02-17       Impact factor: 5.191

Review 4.  TRAF3, ubiquitination, and B-lymphocyte regulation.

Authors:  Wai W Lin; Bruce S Hostager; Gail A Bishop
Journal:  Immunol Rev       Date:  2015-07       Impact factor: 12.988

Review 5.  Cytokines and Signaling Networks Regulating Disease Outcomes in Leishmaniasis.

Authors:  Amrita Saha; Souravi Roy; Anindita Ukil
Journal:  Infect Immun       Date:  2022-07-11       Impact factor: 3.609

6.  Leishmania donovani inhibits macrophage apoptosis and pro-inflammatory response through AKT-mediated regulation of β-catenin and FOXO-1.

Authors:  Purnima Gupta; Supriya Srivastav; Shriya Saha; Pijush K Das; Anindita Ukil
Journal:  Cell Death Differ       Date:  2016-09-23       Impact factor: 15.828

Review 7.  Innate immunity against Leishmania infections.

Authors:  Prajwal Gurung; Thirumala-Devi Kanneganti
Journal:  Cell Microbiol       Date:  2015-08-11       Impact factor: 3.715

Review 8.  The pathogenicity and virulence of Leishmania - interplay of virulence factors with host defenses.

Authors:  Anand Kumar Gupta; Sonali Das; Mohd Kamran; Sarfaraz Ahmad Ejazi; Nahid Ali
Journal:  Virulence       Date:  2022-12       Impact factor: 5.428

Review 9.  Deception and manipulation: the arms of leishmania, a successful parasite.

Authors:  Pedro Cecílio; Begoña Pérez-Cabezas; Nuno Santarém; Joana Maciel; Vasco Rodrigues; Anabela Cordeiro da Silva
Journal:  Front Immunol       Date:  2014-10-20       Impact factor: 7.561

Review 10.  Ubc13: the Lys63 ubiquitin chain building machine.

Authors:  Curtis D Hodge; Leo Spyracopoulos; J N Mark Glover
Journal:  Oncotarget       Date:  2016-09-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.